Tokushima University / Educator and Researcher Directory --- Matsuoka, Ken-ichi

Search:

Research

Field of Study

Subject of Study

Book / Paper

Academic Paper (Judged Full Paper):

1.	Tomoyo Hara, Hiroki Yamagami, Ryoko Uemoto, Akiko Sekine, Yousuke Kaneko, Kohsuke Miyataka, Taiki Hori, Mayuko Shimizu, Masafumi Funamoto, Takeshi Harada, Tomoyuki Yuasa, Shingen Nakamura, Itsuro Endo, Ken-ichi Matsuoka, Yutaka Kawano, Koichi Tsuneyama, Yasumasa Ikeda and Ken-ichi Aihara : Pemafibrate Ameliorates Steatotic Liver Disease Regardless of Endothelial Dysfunction in Mice., Antioxidants, 14, 7, 2025. (Summary) Endothelial dysfunction contributes to the progression of metabolic-dysfunction-associated steatotic liver disease (MASLD). Pemafibrate has been shown to ameliorate MASLD in basic and clinical studies, but it is unclear whether it is also effective in the status of endothelial dysfunction. An MASLD animal model was induced in male wild-type (WT) and endothelial nitric oxide synthase (eNOS)-deficient (eNOSKO) mice by feeding them a high-fat/cholesterol/cholate diet, and they were administered either a vehicle or pemafibrate at 0.17 mg/kg/day for 10 weeks. Although pemafibrate treatment did not change plasma lipid profiles in either WT or eNOSKO mice, pemafibrate reduced plasma AST levels in both WT and eNOSKO mice compared to the levels in the vehicle-treated mice. Histopathological analysis of the liver showed that MASLD was improved in the pemafibrate-treated groups in both WT and eNOSKO mice. Compared to vehicle treatment, pemafibrate treatment significantly reduced the expression levels of hepatic NADPH oxidase subunit genes, M1 macrophages, inflammatory-cytokine-related genes and profibrotic genes in both WT and eNOSKO mice, along with reduction in hepatic oxidative stress assessed by dihydroethidium staining and 4-hydroxynonenal protein levels. Thus, pemafibrate ameliorated MASLD with reduction in oxidative stress and inflammation even in vascular endothelial dysfunction. (Link to Publication Site) ● Publication site (DOI): 10.3390/antiox14070891 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 40722995 ● Search Scopus @ Elsevier (PMID): 40722995 ● Search Scopus @ Elsevier (DOI): 10.3390/antiox14070891 (DOI: 10.3390/antiox14070891, PubMed: 40722995)
2.	Yousuke Kaneko, Yutaka Kawano, Saki Kawata, Kensuke Mori, Minae Hosoki, Taiki Hori, Kohsuke Miyataka, Seijiro Tsuji, Tomoyo Hara, Hiroki Yamagami, Toshiki Otoda, Tomoyuki Yuasa, Akio Kuroda, Takeshi Harada, Hirokazu Miki, Shingen Nakamura, Itsuro Endo, Munehide Matsuhisa, Ken-ichi Matsuoka and Ken-ichi Aihara : Mean Corpuscular Volume Is Correlated with Liver Fibrosis Defined by Noninvasive Blood Biochemical Indices in Individuals with Metabolic Disorders Aged 60 Years or Older., Journal of Clinical Medicine, 14, 13, 4680, 2025. (Summary) Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) causes progressive liver fibrosis. Although erythrocyte mean corpuscular volume (MCV) has been shown to have a positive correlation with all-cause mortality, the association between MCV and the development of MASLD has not been fully elucidated. Here, we examined the clinical significance of the association between MCV and MASLD. Methods: A cross-sectional study was carried out in 1009 Japanese individuals (including 186 individuals aged < 60 years and 823 individuals aged 60 years) with metabolic disorders. The relationships between MCV and noninvasive clinical markers of liver fibrosis, including fibrosis-4 (FIB-4) index, aspartate aminotransferase-to-platelet ratio index (APRI), and non-alcoholic fatty liver disease (NAFLD) fibrosis score (NFS), were statistically evaluated. Results: Using multiple and logistic regression analyses in overall subjects, it was found that MCV was positively and independently associated with the values of FIB-4 index, APRI, NFS, and the prevalence of liver fibrosis defined by each index. However, the associations between the MCV value and MASLD indices were found to be positive in subjects aged 60 years but not in those aged < 60 years. Conclusions: MCV might be a simple and useful biomarker for the development of MASLD in the elderly. (Link to Publication Site) ● Publication site (DOI): 10.3390/jcm14134680 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 40649054 ● Search Scopus @ Elsevier (PMID): 40649054 ● Search Scopus @ Elsevier (DOI): 10.3390/jcm14134680 (DOI: 10.3390/jcm14134680, PubMed: 40649054)
3.	SooHa Kim, Jumpei Teramachi, Masahiro Hiasa, Ryota Amachi, Ariunzaya Bat-Erdene, Asuka Oda, Hirofumi Tenshin, Mariko Tanaka, Motosumi Nakagawa, Aiko Seki, Yoshihiko Sawa, Ken-ichi Matsuoka, Eiji Tanaka, Takeshi Harada, Tatsuya Tominaga and Masahiro Abe : Myeloma cell growth suppression by osteoblast-derived extracellular vesicles: the creation of a non-permissive niche for myeloma cells by bone-forming osteoblasts., Haematologica, 110, 6, 1395-1401, 2025. (Summary) Not available. (Tokushima University Institutional Repository) ● Metadata: 2013272 (Link to Publication Site) ● Publication site (DOI): 10.3324/haematol.2024.286554 (Link to Search Site for Scientific Articles) ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 39844765 ● Search Scopus @ Elsevier (PMID): 39844765 ● Search Scopus @ Elsevier (DOI): 10.3324/haematol.2024.286554 (Tokushima University Institutional Repository: 2013272, DOI: 10.3324/haematol.2024.286554, PubMed: 39844765)

Proceeding of Domestic Conference:

1.	Ken-ichi Aihara, Tomoyo Hara, Hiroki Yamagami, 上元良子, 関根明子, KANEKO Yohsuke, MIYATAKA Kosuke, Tomoyuki Yuasa, Shingen Nakamura, Yutaka Kawano, Itsuro Endo, Ken-ichi Matsuoka and Yasumasa Ikeda : ペマフィブラートは血管内皮機能障害の有無に関わらずマウスMASLD 病態を改善する, 第57回日本動脈硬化学会総会・学術集会, Jul. 2025.
2.	Ken-ichi Aihara, 上元良子, 関根明子, Tomoyuki Yuasa, Yutaka Kawano, Shingen Nakamura, Tomoyo Hara, Hiroki Yamagami, Yohsuke Kaneko, Kosuke Miyataka, Ken-ichi Matsuoka, Itsuro Endo and Yasumasa Ikeda : eNOS欠損MASLDモデルマウスにおけるペマフィブラートの影響に関する検討, 第98回日本内分泌学会学術総会, Jun. 2025.
3.	金子遥祐, 河田沙紀, 森建介, 細木美苗, 堀太貴, 宮髙紘輔, 辻誠士郎, Tomoyo Hara, Hiroki Yamagami, Toshiki Otoda, Tomoyuki Yuasa, Yutaka Kawano, Shingen Nakamura, Akio Kuroda, Itsuro Endo, Munehide Matsuhisa, Ken-ichi Matsuoka and Ken-ichi Aihara : 代謝異常関連脂肪性肝疾患と赤血球Mean Corpuscular Volume の連関解析, 第68回日本糖尿病学会年次学術集会, May 2025.
4.	八木萌香, Tomoyo Hara, 坂尾祐佳子, 佐藤寛子, 浅井孝仁, 安井沙耶, Hiroki Yamagami, Tomoyuki Yuasa, Kazuhiro Nomura, Akio Kuroda, Shingen Nakamura, Itsuro Endo, Munehide Matsuhisa, Hiroshi Sakaue, Ken-ichi Matsuoka and Ken-ichi Aihara : 糖尿病関連腎臓病におけるフィブリノゲン/アルブミン比の意義に関する臨床的検討, 第68回日本糖尿病学会年次学術集会, May 2025.
5.	Ken-ichi Aihara, Tomoyo Hara, Hiroki Yamagami, 金子遥祐, 宮髙紘輔, 堀太貴, Tomoyuki Yuasa, Hiroyasu Mori, Akio Kuroda, Shingen Nakamura, Itsuro Endo, Ken-ichi Matsuoka and Munehide Matsuhisa : 生体電気インピーダンス法による位相角の糖尿病関連腎臓病における臨床的意義, 第68回日本糖尿病学会年次学術集会, May 2025.
6.	Ken-ichi Aihara, Tomoyo Hara, Hiroki Yamagami, Yohsuke Kaneko, Kosuke Miyataka, Taiki Hori, Tomoyuki Yuasa, Hiroyasu Mori, Akio Kuroda, Shingen Nakamura, Itsuro Endo, Ken-ichi Matsuoka and Munehide Matsuhisa : 生体電気インピーダンス法による位相角の糖尿病関連腎臓病における臨床的意義, 第68回日本糖尿病学会年次学術集会, May 2025.
7.	Tomoyo Hara, 八木萌香, 坂尾祐佳子, 佐藤寛子, 浅井孝仁, 安井沙耶, Hiroki Yamagami, Tomoyuki Yuasa, Akio Kuroda, Shingen Nakamura, Itsuro Endo, Munehide Matsuhisa, Ken-ichi Matsuoka, Ken-ichi Aihara, 柚山賀彦, 鴻山訓一, 楠宜樹, 大東真菜, 目黒周, 伊藤新, 岡田浩 and 坂根直樹 : 2型糖尿病患者における可溶型DPP-4/CD26と代謝機能障害関連脂肪性肝疾患の関連, 第68回日本糖尿病学会年次学術集会, May 2025.
8.	森本くるみ, 玉谷香住里, 山本英之, 新居清美, 三木こずえ, Yoshie Imai, Yusaku Maeda, Ryohei Sumitani, Masahiro Oura, Kimiko Sogabe, 八木ひかる, Takeshi Harada, Shiroh Fujii, Shingen Nakamura, Hirokazu Miki and Ken-ichi Matsuoka : 同種造血幹細胞移植を受けた壮年期患者の原動力, 第47回日本造血・免疫細胞療法学会総会, Mar. 2025.
9.	阪本朋香, Yoshie Imai, 三木こずえ, Shiroh Fujii, Hirokazu Miki, Kimiko Sogabe, Masahiro Oura, Ryohei Sumitani, 八木ひかる, 高橋真美子, Takeshi Harada, 前田悠作, Shingen Nakamura and Ken-ichi Matsuoka : 治療過程にある多発性骨髄腫患者が治療を続ける意味, 第39回日本がん看護学会学術集会, Feb. 2025.